Categories
Change Password!
Reset Password!
To evaluate the effectiveness of Adalimumab among individuals with erosive hand osteoarthritis (OA).
An erosive hand osteoarthritis is a form of hand
osteoarthritis. The phase of the normal process or separate entity and remains
debated. It is defined by radiographic erosions with a central subchondral bone
collapse. Therefore, the outcomes of this research demonstrated that the
adalimumab (40 mg subcutaneous injections) did not show any effect on patients
with erosive hand OA with MRI-detected synovitis as compared to placebo after
12 weeks.
To evaluate the effectiveness of Adalimumab among
individuals with erosive hand osteoarthritis (OA).
The individuals met the American College of
Rheumatology (ACR) criteria for hand OA, with >30 min morning
stiffness, ≥1 erosive joint on X-ray
with synovitis, and >50 on 100 mm visual analogue scale scores with age
of >50 years old were selected for
the study. Two groups were formed; one received 40 mg subcutaneous injections
of Adalimumab every other week, and other group received identical placebo
injections for 12 weeks, succeeded by an 8-week washout and later crossed over
medication groups for another 12 weeks. Change in VAS hand pain over 12 weeks
was taken as the primary endpoint.
Function and stiffness subscales from baseline to 4, 8 and 12 weeks,
change in Australian/Canadian Hand OA Index (AUSCAN) pain, change in VAS from
baseline to 4 and eight weeks, a change in MRI-detected synovitis and bone
marrow lesions (BMLs) from baseline to 12 weeks were taken as study's secondary
endpoints.
A total of 43 subjects categorised either group one or
group two. No change was seen between the groups regarding primary endpoint at
12 weeks. The adjusted treatment effect found to be -0.7 mm. Secondary
endpoints also exhibited no statistically significant differences.
As compared to placebo, Adalimumab did not present any
impact on synovitis, pain, or BMLs among patients with erosive hand OA with
MRI-detected synovitis.
Osteoarthritis Cartilage. 2018 Feb 27.
A randomised double-blind placebo-controlled crossover trial of HUMira (adalimumab) for erosive hand OsteoaRthritis - The HUMOR trial
Lesley M. Arnold et al.
Comments (0)